Inhibrx Biosciences, Inc. (INBX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Inhibrx Biosciences, Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 9 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 82.10 $ — 51% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
NeutralKlinisches Biotechunternehmen ohne KI-Produkt und ohne KI-Umsatz; künstliche Intelligenz taucht in den geprüften Filings nur als beiläufiger Hinweis auf, dass Mitarbeiter generative KI-Werkzeuge nutzen dürfen — eingebettet in ein Geschäftsgeheimnis-Risiko, nicht als Geschäftsmodell oder wesentliches Risiko.
View the full file — quotes, sources, reviewed filings
„Our employees can use generative artificial intelligence ("AI") technologies in certain circumstances to perform portions of their work. There can be no assurance that employees will not inadvertently or improperly input information that is proprietary, confidential, or sensitive, including trade secrets, into AI systems in a manner that results in unauthorized disclosure or loss of confidentiality."
Unsere Mitarbeiter dürfen unter bestimmten Umständen generative Technologien der künstlichen Intelligenz („KI“) einsetzen, um Teile ihrer Arbeit zu erledigen. Es kann nicht zugesichert werden, dass Mitarbeiter nicht versehentlich oder unsachgemäß geschützte, vertrauliche oder sensible Informationen – einschließlich Geschäftsgeheimnissen – so in KI-Systeme eingeben, dass es zu einer unbefugten Offenlegung oder zum Verlust der Vertraulichkeit kommt.
„We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms."
Wir sind ein Biopharma-Unternehmen im klinischen Stadium mit einer Pipeline neuartiger biologischer Wirkstoffkandidaten, die mithilfe unserer firmeneigenen modularen Protein-Engineering-Plattformen entwickelt werden.
Filings Reviewed: 10-K 2026-03-19 · 10-K 2025-03-17 · 10-Q 2026-05-14 · 10-Q 2025-11-14 · 10-Q 2025-08-13 · 10-Q 2025-05-14
Rated on July 10, 2026 · How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -16.0% failed
- More than 10% revenue growth is expected for the coming year 0.0% failed
- Share count grows by less than 3% a year -27.2% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -9,436.5% failed
- Gross margin at 40% or higher and without meaningful erosion -91.0% failed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 17 m net cash passed
- Operating cash flow covers the profits of the last three years -1,824 m failed
- Return on capital at 15% or higher, or up versus two years ago -119.8% failed
- Insiders hold at least 10% or are net buyers 23.2% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 238.0% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -9.26 | -9.26 – -9.26 | 0 | -2.4% | 1 |
| 12/31/2027 | -6.30 | -6.30 – -6.30 | 57 | 32.0% | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -2.50 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -3.31 | – | 0 | -93.90 | -47,865.00 | -44 | -44 |
| 2025: Q1 | -2.80 | – | 0 | – | – | -36 | -36 |
| 2025: Q2 | -1.85 | -101.50 | 1 | 1,200.00 | -2,204.20 | -30 | -30 |
| 2025: Q3 | -2.28 | – | 0 | – | – | -34 | -34 |
| 2025: Q4 | -2.12 | – | 0 | -100.00 | – | -30 | -30 |
| 2026: Q1 | -2.15 | – | 0 | – | – | -38 | -38 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 7 | -12 | -8 | -0.23 | -18 | -9 | 21 |
| 2017 | 8 | -20 | -19 | -0.68 | -19 | -29 | 17 |
| 2018 | 8 | -30 | -31 | -1.15 | -23 | -58 | 10 |
| 2019 | 9 | -44 | -51 | -1.41 | -32 | -94 | 26 |
| 2020 | 13 | -67 | -76 | -2.99 | -48 | 75 | 144 |
| 2021 | 7 | -77 | -82 | -2.15 | -80 | 52 | 150 |
| 2022 | 2 | -129 | -145 | -3.62 | -115 | 58 | 291 |
| 2023 | 2 | -219 | -241 | -5.12 | -193 | 44 | 308 |
| 2024 | 0 | -331 | 1,688 | 116.58 | -194 | 134 | 181 |
| 2025 | 1 | -135 | -140 | -9.04 | -130 | 8 | 146 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Inhibrx Biosciences, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, beschäftigt sich mit der Entwicklung biologischer Therapeutika für Menschen mit lebensbedrohlichen Erkrankungen.
| Employees | 109 |
|---|---|
| Headquarters | La Jolla, CA |
| Address | 11025 North Torrey Pines Road, 92037 La Jolla, United States |
| Phone | 858 795 4220 |
| Website | inhibrx.com |
| IPO Date | 29. May 2024 |
| ISIN | US45720N1037 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Mark Paul Lappe | Founder, CEO & Chairman | 1967 |
| David J. Matly M.B.A. | President | 1986 |
| Kelly Devine Deck B.S., CPA, M.S. | Executive VP, CFO & Treasurer | 1980 |
| Bonne Adams M.B.A. | Vice President of Operations | 1977 |
| Kate Burke CPA, M.B.A. | Vice President of Accounting | – |
| Ashraf Amanullah Ph.D. | Executive VP & Chief Technical Operations Officer | 1968 |
| Carlos Bais Ph.D. | EVP & Chief Scientific Officer | – |
| Leah Pollema J.D. | VP, General Counsel & Corporate Secretary | – |
| Josep Garcia Ph.D. | Executive VP & Chief Clinical Development Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.